How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks

North Chicago, Illinois-based AbbVie Inc. (ABBV) is a global, research-driven biopharmaceutical company focused on developing and commercializing medicines for complex and serious diseases. Valued at a market cap of $386.3 billion, its key therapeutic areas include immunology, neuroscience, oncology and aesthetics, with operations spanning more than 75 countries.

Companies with a market capitalization of $200 billion or more are typically referred to as "mega-cap stocks." ABBV fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry.  AbbVie combines a large established pharmaceutical portfolio with a rapidly expanding immunology franchise and a broad pipeline.

However, the stock currently trades 10.5% below its 52-week high of $267.41 recorded on Oct. 01, 2025. ABBV has surged 16.9% over the past three months, outpacing the State Street Health Care Select Sector SPDR ETF’s (XLV) 13.4% gain. 

The stock has grown 22.9% over the past 52 weeks and 11.8% on a YTD basis, compared to XLV’s 25.5% rally over the past year and 10.6% rise in 2026. 

ABBV has been trading below its 200-day moving average since April and above its 50-day moving average. 

On July 31, AbbVie delivered a strong Q2 2026, with revenue rising 10.2% year over year to $16.99 billion and adjusted EPS jumping 22.9% to $3.65. However, investors focused on the near-term cost of AbbVie’s $10.9 billion Apogee Therapeutics acquisition, which is expected to dilute 2026 adjusted EPS by $0.14, partially offset by $0.10 of stronger-than-expected underlying performance. As a result, AbbVie lowered its full-year adjusted EPS outlook by $0.04 at the midpoint to $13.97, sending shares down 2.5%. 

When stacked against its rival, Johnson & Johnson (JNJ) has surged 52.8% over the past year and 29.5% in 2026, outperforming ABBV. 

Wall Street currently holds a moderately optimistic view of the stock. Among the 31 analysts tracking ABBV, the overall consensus stands at a “Strong Buy.” Its mean price target of $276.37 suggests 8.2% upside potential from current price levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.